Immuneering Corp (IMRX)
$2.02
+0.59
(+41.26%)▲
Performance
- $1.85$2.54$2.02
8.42%
Downside
Day's Volatility :27.14%
Upside
20.44%
- $1.00$9.00$2.02
50.5%
Downside
52 Weeks Volatility :88.89%
Upside
77.56%
Returns
| Period | Immuneering Corp | Index (Russel 2000) |
|---|---|---|
3 Months | 33.77% | 0.0% |
6 Months | -30.34% | 0.0% |
1 Year | -73.63% | 0.0% |
3 Years | -92.19% | -20.0% |
Highlights
Market Capitalization | 42.4M |
Book Value | $2.24 |
Earnings Per Share (EPS) | -1.9 |
Wall Street Target Price | 11.07 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.42% |
Return On Equity TTM | -61.81% |
Revenue TTM | 455.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -99.8% |
Gross Profit TTM | 158.8K |
EBITDA | -60.1M |
Diluted Eps TTM | -1.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.89 |
EPS Estimate Next Year | -1.64 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.53 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 448.02%
Technicals Summary
Sell
Neutral
Buy
Immuneering Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Immuneering Corp | 87.04% | -30.34% | -73.63% | -92.19% | -88.52% |
 Regeneron Pharmaceuticals, Inc. | -0.3% | 20.26% | 38.56% | 78.77% | 303.42% |
 Novo Nordisk A/s | 1.92% | 1.8% | 42.06% | 173.92% | 453.76% |
 Alnylam Pharmaceuticals, Inc. | 0.91% | 78.6% | 37.4% | 41.12% | 212.93% |
 Vertex Pharmaceuticals Incorporated | 2.95% | 18.74% | 38.91% | 157.61% | 173.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Immuneering Corp | NA | NA | NA | -1.89 | -0.62 | -0.37 | NA | 2.24 |
Regeneron Pharmaceuticals, Inc. | 30.86 | 30.86 | 1.59 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.01 | 46.01 | 2.08 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Immuneering Corp | Buy | $42.4M | -88.52% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $128.4B | 303.42% | 30.86 | 32.04% |
Novo Nordisk A/s | Buy | $600.4B | 453.76% | 46.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 212.93% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.3B | 173.37% | 32.84 | -4.74% |
Insights on Immuneering Corp
Decreasing Revenue
Revenue is down for the last 2 quarters, 94.41M → -94.41M (in $), with an average decrease of 200.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -15.08M → -14.07M (in $), with an average increase of 3.5% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 115.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 173.9% return, outperforming this stock by 266.1%
Institutional Holdings
Vanguard Group Inc
3.61%Millennium Management LLC
3.21%T. Rowe Price Associates, Inc.
2.90%Goldman Sachs Group Inc
2.50%Prosight Management, LP
1.85%BlackRock Inc
1.80%
Company Information
Organization | Immuneering Corp |
Employees | 66 |
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.02
+41.26%
Keyarch Acquisition Corp
$2.02
+41.26%
Connexa Sports Technologies Inc
$2.02
+41.26%
Us Value Etf
$2.02
+41.26%
First Wave Biopharma Inc
$2.02
+41.26%
Global X Msci Next Emerging
$2.02
+41.26%
Fat Projects Acquisition Corp
$2.02
+41.26%
Capital Link Global Fintech
$2.02
+41.26%
Applied Uv Inc
$2.02
+41.26%